Steven Gillon, DO
Gastroenterology · Englewood, NJNPI 1285668376
Payments from drug & device makers
Across 154 payments — averaging $14.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$652
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$390
- Novo Nordisk$228
- AstraZeneca$183
- Pfizer$131
- Gilead$118
- plus $545 from 17 others
What the payments were for
- Food & beverage$2,19298%
- Education$552%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 60 | $652 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $390 |
| Novo Nordisk | 16 | $228 |
| AstraZeneca | 7 | $183 |
| Pfizer | 9 | $131 |
| Gilead | 8 | $118 |
| Redhill Biopharma Inc. | 7 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $75 |
| Johnson & Johnson(2 entities) | 4 | $62 |
| QOL Medical, LLC | 4 | $52 |
| Medtronic | 1 | $39 |
| Intercept Pharmaceuticals, Inc. | 2 | $28 |
| Shionogi Inc | 2 | $25 |
| Ironwood Pharmaceuticals, Inc | 2 | $24 |
| Ardelyx, Inc. | 1 | $22 |
| Exact Sciences | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Dova Pharmaceuticals | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| GSK | 1 | $14 |
| Celltrion USA Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Bristol Myers Squibb | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,246 in reported general payments places this provider in the 45th percentile of 701 gastroenterology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VemlidyTenofovir Alafenamide | 13 | $17,197 |
| OzempicSemaglutide | 11 | $16,470 |
| CreonLipase/Protease/Amylase | 17 | $15,481 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $10,374 |
| PaxlovidNirmatrelvir/Ritonavir | 11 | $1,429 |
| Pantoprazole Sodium | 57 | $844 |
| Atorvastatin Calcium | 55 | $739 |
| Esomeprazole Magnesium | 13 | $663 |
| Telmisartan | 12 | $460 |
| Famotidine | 42 | $460 |
| Metoprolol Succinate | 24 | $436 |
| Solifenacin Succinate | 12 | $436 |
| Alprazolam | 98 | $434 |
| Rosuvastatin Calcium | 26 | $408 |
| Omeprazole | 19 | $376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadVemlidy | $118 | $17,19713 claims |
| Novo NordiskOzempic | $228 | $16,47011 claims |
| AbbVieCreon | $652 | $15,48117 claims |
| GSKTrelegy Ellipta | $14 | $10,37417 claims |
| PfizerPaxlovid | $131 | $1,42911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 701 gastroenterology providers in New Jersey.
Other gastroenterology in Englewood
- Kenneth RubinEnglewood$297K
- Mark SapienzaEnglewood$81K
- Kiran RaoSparta$1.3M
- Adekunle AdeotiIrvington$1.2M
- Carl WallachMorristown$766K
- Vinod RustgiNew Brunswick$697K
- Arvind TrindadeNew Brunswick$652K
- Barry KaufmanEgg Harbor Township$595K
- Promila BanerjeeStratford$522K
- Neil NagariaToms River$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.